Biopharmaceutical manufacturers increasingly depend on external innovation to complement internal pipelines and expand development capabilities. Licensing, co-development and investment decisions can determine how promising technologies move toward commercialization. BioPharma Deals 2026 will bring business development and licensing professionals together in Munich on November 24 and 25, 2026, for discussions focused on these commercial priorities.

The summit will bring together pharmaceutical and biotechnology companies alongside investors, service providers and other participants in the life sciences transaction ecosystem. Its agenda centers on licensing deals, alliances, mergers and acquisitions, corporate partnerships, co-development and external innovation. This focused structure places commercial strategy alongside the scientific opportunities being evaluated by deal teams.

Partnering will be a major component of the event. The program includes pre-arranged one-to-one meetings that allow participants to identify organizations with relevant partnering interests before arriving in Munich. The format is designed to support focused conversations around potential licensing agreements, investments and strategic collaborations rather than relying solely on general conference networking.

Due diligence and corporate development add another layer to the agenda. Pharmaceutical companies assessing external assets must consider how an opportunity fits their broader portfolio and development strategy, while biotechnology companies need to communicate their assets and commercial objectives clearly to potential counterparts. These considerations make deal-making closely connected with longer-term pipeline planning.

The event also provides a setting for investors and advisors to engage with companies pursuing growth through partnerships. Company presentations and executive discussions will complement the one-to-one meetings, creating several points of interaction across the transaction process. The summit is scheduled at the Science Congress Center Munich, within a major European life sciences cluster.

The Manufacturing Outlook is serving as a media partner because the commercial development of biopharmaceutical technologies also intersects with manufacturing strategy, process capabilities and industrial innovation. The publication covers manufacturing technologies, AI, automation and emerging industrial systems for an executive audience across manufacturing sectors. Editorial coverage can extend the Munich discussions by examining how strategic life sciences partnerships can influence the technologies and capabilities required to manufacture advanced products at scale.

BioPharma Deals 2026 places commercial strategy at the center of life sciences innovation. Its Munich program provides a focused environment for examining how licensing, investment and partnerships can connect emerging technologies with the capabilities needed to advance biopharmaceutical development.